Table 2. Patient characteristics.
| Cohort 1 (n=22) | Cohort 2 (n=15) | Patients with a mutation | |
|---|---|---|---|
| Age | |||
| • Children (<18 years) | 6 (27.3%) | 2 (13.3%) | 1 (12.5%) |
| • Adult (≥18 years) | 16 (72.7%) | 13 (86.7%) | 7 (24.1%) |
| (p = NS) | |||
| Sex | |||
| • Male | 16 (72.7%) | 6 (40%) | 6 (27.3%) |
| • Female | 6 (27.3%) | 9 (60%) | 2 (13.3%) |
| (p = NS) | |||
| Tumor localization | |||
| • Extremity | 12 (54.5%) | 9 (40%) | 4 (19.0%) |
| • Non-extremity | 9 (40.9%) | 6 (60%) | 4 (26.7%) |
| • Unknown | 1 (4.5%) | 0 | 0 |
| (p = NS) | |||
| Histology | |||
| • Monophasic | 11 (50%) | 10 (66.7%) | 4 (19.0%) |
| • Biphasic | 8 (36.4%) | 3 (20%) | 3 (27.3%) |
| • Unknown | 3 (13.6%) | 2 (13.3%) | 1 (20.0%) |
| (p = NS) | |||
| Translocation | |||
| • SSX1 | 14 (63.6%) | 11 (73.3%) | 6 (24.0%) |
| • SSX2 | 8 (36.4%) | 4 (26.7%) | 2 (16.7%) |
| (p = NS) | |||
| Follow up | |||
| • 5 year overall survival | 62% | 67% | 29.2% |
| (p = 0.026) | |||
NS = not significant (p > 0.05)